This application discloses compounds according to generic Formula I:wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.本申請案揭示抑制Btk之通式I化合物:其中所有變數均如本文所述定義。本文揭示之化合物適用於調節Btk活性及治療與過度Btk活性有關之疾病。該等化合物另外適用於治療與異常B細胞增殖有關之發炎及自體免疫疾病,諸如類風濕性關節炎。亦揭示含有式I化合物及至少一種載劑、稀釋劑或賦形劑之組合物。